Emerging options for the treatment of type 2 diabetes in Chinese patients: Focus on arterial function and alogliptin

Abstract

Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People’s Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calcifcation, and – finally – to an increase in arterial stiffness and arterial dysfunction. Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its great antihyperglycemia effect in T2DM patients. The clinical trial data from the People’s Republic of China was similar to other global and Asian trials. This could provide some choice for clinical physicians to the treatment of T2DM.